In Silico Study on Estrogens Receptor Modulators as Anti-cancer Agents

Authors

  • Azmin M Mogal Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Gujarat
  • Malleshappa N Noolvi Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Gujarat
  • Uttam A More Associate professor Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Gujarat

Abstract

The clinical selective estrogen receptor modulator tamoxifen is most commonly used drug for the treatment of estrogen positive breast cancer and has been preventing lives worldwide. The pioneering drug; tamoxifen used in both treatment and prevention of estrogen positive breast cancer and also addressing new research for selective estrogen receptor modulators (SERMs). Based on these for current study 20 tamoxifen derivatives has been designed for in silico study. For the present work, we had already selected known estrogen modulators along with 20 designed molecules for molecular docking study against estrogen using PDB 3ERT. Designed molecules showed docking interaction with active site amino acids by hydrogen bond as well as VDW interactions. The knowledge obtained from this study like, total energy, and interaction with amino acids suggested necessary binding interactions used to optimize lead molecule. These findings can be utilizing for development of new anticancer agents with reduced side effects.

 

Keywords: Tamoxifen derivatives, estrogens receptor modulators, anti-cancer agents

Tamoxifen derivatives

Downloads

Published

2019-01-17

Issue

Vol. 5 No. 3 (2018)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.